| Popis: |
03325 The tetanus antibody levels in the people living with HIV in a Turkish HIVcare centre10. Immunology & VaccinologyA. Nazli 1, B. Kenanoglu 2, M. Isikgoz Tasbakan 2, H. Pullukcu 2, A. Zeytinoglu 3, D. Gokengin 31Dokuz Eylul University Medical Faculty Infectious Diseases and Clinical MicrobiologyDepartment - Izmir (Turkey), 2Ege University Medical Faculty Infectious Diseases andClinical Microbiology Department - Izmir (Turkey), 3Ege University Medical Faculty MedicalMicrobiology Department - Izmir (Turkey)BackgroundEven in the golden age highly active antiretroviral therapy, the people living with HIVhave risk of complications from vaccine-preventable diseases. In Turkey, adults wereroutinely vaccinated during pregnancy or military service and recommended a rappeldose after 10 years. There is a lack of routine vaccination program for the peopleliving with HIV. We aimed to investigate the levels of tetanus antibody levels and thefactors related in the people living with HIV who attended our centre.MethodsWe included the people living with HIV who attended Ege University Medical FacultyInfectious Disease HIV care outpatient clinic who accepted the informed consent togive blood sample. We used Enzyme-Linked Immuno Sorbent Assay kit to testtetanus antitoxin IgG levels. We recorded age, sex, the vaccination history, CD4 Tcell count during vaccination, the time of HIV diagnosis retrospectively.ResultsWe included 146 people living with HIV in our study. The 86, 3% was male sex. Themean age was 39.5 years (±11.20). The mean CD4 T cell count was 485 ±279.18 (1-1331) / mm3. One hundred and fourteen (78.1%) participants had the protectiveantibody level. The rappel dose recommendations according to antibody levelwere immediate rappel dose to 32 (21.9%), in five years to 37(25.3%), in ten yearsto 69 (47.3%) and after ten years to eight (5.5%) participants. In the multi variateanalysis, the related factors for protective antibody level were CD4 T cell count>218/ mm3 during vaccination (p= 0,043, OR: 4.28; 95 % CI(1,05-17,44) and age ≥43 years (p= 0,0001, OR:30,6 (6,51-144,2). One hundred seven (73.2 %)participants had vaccination history. The duration of vaccination and the antibodylevels were uncorrelated.ConclusionsThe protective antibody levels for tetanus vaccine were low independent of thevaccination time in the people living with HIV. In every five years, testing of tetanusantibody level or rappel dose can protect them for the future infections. |
